Lionic Labs S23

S23 exhibits a high affinity for the androgen receptor with tissue selective anabolic effects in muscle and bone, with relatively less stimulation of the prostate, seminal vesicles and other androgen affected tissues.

S-23 was developed by GTx. Research has shown S-23 is an orally active nonsteroidal SARM, and it has a very high binding affinity to androgen receptors. This makes it one of the strongest SARMS. Research shows that the main effects of S-23 are increased muscle mass, decreased fat mass, and a decrease in the size of the prostate. Cell studies have shown that S23 establishes very strong bonds with androgen receptors, making S23 one of the most potent SARMS currently available.

The action of S23 on muscles and bones is complex. In general, when a SARM binds to an androgen receptor it increases the activity of genes that make muscle proteins. Activated receptors can also send signals to increase the activity of bone-building cells. The contraceptive effects of S23 are due to its ability to suppress FSH and LH, two key hormones for making sperm. However, this effect disappears at higher doses. S23 decreases fat in a dose-dependent manner. 

S23 is a Selective Androgen Receptor Modulator (SARM) currently under development for potential use as a male hormonal contraceptive. It is still in the preclinical stage of development, meaning it has only been tested on animals, not humans.

Researchers are putting in considerable effort to develop the "male pill", seeking a substance that would be both safe and effective. S23 shows promise as a contraceptive for men because it can suppress hormones (FSH and LH) that are important for sperm production.

Cycle Length: 6-8 Weeks (Max)
10mg/ml | 30ml
Do not exceed 20ml per day